Akèy › Kansè tete negatif triple › Georgia › Atlanta
Etid klinik pou Kansè tete negatif triple nan Atlanta, GA
20 etid pou Kansè tete negatif triple ap chèche patisipan nan sit nan ak bò kote Atlanta (nan yon distans apeprè 30 mil). Louvri yon etid pou wè ki moun ki ka patisipe ak kijan pou kontakte ekip etid la.
Tèks ofisyèl etid la (Anglè)
Ap chèche patisipan pou yon etid? Mete l anwo paj sa a — $99 pou 30 jou →
A Phase 1 Study of PLN-101095 in Adults With Advanced or Metastatic Solid Tumors
Ap rekriteFaz 1
- Winship Cancer Institute of Emory University, Atlanta
A Study of LY4052031 in Participants With Advanced or Metastatic Urothelial Cancer or Other Solid Tumors
Ap rekriteFaz 1
- Emory University, Atlanta
A Study With NKT3964 for Adults With Advanced/Metastatic Solid Tumors
Ap rekriteFaz 1
- Emory Winship Cancer Institute, Atlanta
A Study of SDX-7320 in Combination With Eribulin for People With Breast Cancer
Ap rekriteFaz 2
- Emory University (Data Collection Only), Atlanta
Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Ap rekriteFaz 3
- Piedmont Cancer Institute, Atlanta
- Northside Hospital, Atlanta
A Study of Sofe-M in Participants With Selected Advanced Solid Tumors
Ap rekriteFaz 1
- Emory University, Atlanta
Toci +/- SOC Chemo for Metastatic Triple Negative and ER-positive, HER2-negative Breast Cancers
Ap rekriteFaz 2
- Emory University, Atlanta
ProAgio in Combination With Gemcitabine in Patients With Metastatic Triple Negative Breast Cancer
Ap rekriteFaz 1/2
- Emory University Winship Cancer Institute, Atlanta
- Winship Cancer Institute of Emory University, Atlanta
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
Ap rekriteFaz 2/3
- Northside Hospital, Atlanta
A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors
Ap rekriteFaz 1/2
- Winship Cancer Institute, Emory University, Atlanta
Study of XB010 in Subjects With Solid Tumors
Ap rekriteFaz 1
- Winship Cancer Institute, Atlanta
BAL0891 in Patients With Advanced Solid Tumors or Relapsed or Refractory Acute Myeloid Leukemia
Ap rekriteFaz 1
- Winship Cancer Institute / Emory University, Atlanta
Propranolol and Pembrolizumab for Tumor Re-sensitization and Treatment of Patients With Checkpoint Inhibitor Refractory Metastatic or Unresectable Triple Negative Breast Cancer
Ap rekriteFaz 2
- Emory University Hospital, Atlanta
Evaluating and Monitoring Immune and Clinical Responses in Early-Stage Triple Negative Breast Cancer Undergoing Neoadjuvant Chemo-immunotherapy With Pembrolizumab
Ap rekriteEtid obsèvasyonVolontè an sante akeyi
- Emory University/Winship Cancer Institute, Atlanta
I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer
Ap rekriteFaz 2
- Winship Cancer Institute of Emory University, Atlanta
High Dose Radiation Therapy With Pembrolizumab and Chemotherapy for the Treatment of Patients With PD-L1 Positive Metastatic Triple Negative Breast Cancer
Ap rekriteFaz 2
- Emory University Hospital/Winship Cancer Institute, Atlanta
Safety Study of MELK Inhibitor to Treat Patients With Advanced Breast Cancer and Triple Negative Breast Cancer
Ap rekriteFaz 1
- Emory University, Winship Cancer Institute, Atlanta
A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer
Ap rekriteFaz 1/2
- Winship Cancer Institute - Emory University, Atlanta
Personalized Vaccine Immunotherapy in Combination With Checkpoint Inhibitor for Treatment of Triple Negative Breast Cancer
Ap rekriteFaz 1
- Grady Health System, Atlanta
- Emory University Hospital Midtown, Atlanta
- Emory University Hospital/Winship Cancer Institute, Atlanta
- ak 1 plis
A Beta-only IL-2 ImmunoTherapY Study
Ap rekriteFaz 1/2
- Emory - Winship Cancer Institute, Atlanta
Etid Kansè tete negatif triple nan lòt vil
- Houston, TX42 etid
- New York City, NY31 etid
- Nashville, TN28 etid
- Los Angeles, CA27 etid
- Boston, MA26 etid
- San Antonio, TX23 etid
- St. Louis, MO21 etid
- Arlington, VA20 etid
- Dallas, TX18 etid
- Chicago, IL16 etid
- Columbus, OH16 etid
- Grand Rapids, MI15 etid
Lòt etid nan Atlanta
- Kansè (tout kalite)49 etid
- Kansè Poumon ki pa ti selil47 etid
- Myelom Miltip42 etid
- Kansè nan tete41 etid
- Kansè pwostat33 etid
- Leksemi mieloïd egi31 etid
- Kansè ovè29 etid
- Kansè kolorektal29 etid
- Kansè poumon29 etid
- Kansè Metastatik28 etid
- Twoub depresif majè25 etid
- Ensifizyans kadyak25 etid
Sous ClinicalTrials.gov, done yo ranmase Oct 6, 2026. Chak etid gen kritè li pou li menm; ekip etid la deside ki moun ki ka patisipe.